葡萄胎后妊娠滋养细胞肿瘤诊断时及随访中的超声特征及其与甲氨蝶呤耐药的关系
该回顾性研究纳入36例在瑞典卡罗林斯卡大学医院接受一线甲氨蝶呤治疗的葡萄胎后妊娠滋养细胞肿瘤女性,分析诊断时及随访中的经阴道超声特征与甲氨蝶呤耐药的关系。诊断时78%存在子宫病变,随访中88%(21/24)病变完全消退,中位消退时间6.8个月;甲氨蝶呤耐药者中子宫肿瘤≥4 cm和全局性病变更常见。
要点
- 葡萄胎后GTN诊断时78%可检出子宫病变,其中67%为局灶性、11%为全局性。
- 病变最大径中位40.4 mm,93%(26/28)彩色评分3或4分,32%(9/28)见动静脉瘘。
- 甲氨蝶呤耐药者子宫肿瘤≥4 cm(73% vs 17%,P=0.008)和全局性病变(25% vs 0%,P=0.03)更常见。
核心结论
- 葡萄胎后GTN诊断时78%可检出子宫病变,绝大多数病变在随访中完全消退,中位消退时间约7个月。
- 甲氨蝶呤耐药在子宫肿瘤≥4 cm或全局性病变者中更常见。
研究设计与样本
- 回顾性研究,纳入2010年10月至2017年12月在瑞典斯德哥尔摩卡罗林斯卡大学医院接受一线甲氨蝶呤治疗的葡萄胎后GTN女性,47例符合条件中36例纳入分析。
- 纳入条件为一线甲氨蝶呤开始前≤2周或开始后≤1周内接受过专家经阴道超声评估。
- 参考标准为甲氨蝶呤耐药(MTX-R)的发生及人绒毛膜促性腺激素正常化。
关键影像表现/征象
- 诊断时8例(22%)无子宫病变,24例(67%)为局灶性病变,4例(11%)为全局性病变。
- 病变最大径中位40.4 mm(IQR 31.3-49.4),26/28(93%)彩色评分3或4分。
- 动静脉瘘见于9/28(32%),黄素化囊肿见于4/36(11%)。
- 随访中88%(21/24)病变完全消退,血管消失中位时间5.8个月(IQR 3.7-9.3),病变消退中位时间6.8个月(IQR 3.7-9.3)。
诊断标准与关键数值
- 甲氨蝶呤耐药发生于12/31(39%)女性。
- 子宫肿瘤≥4 cm在耐药组为73%、非耐药组为17%(P=0.008)。
- 全局性病变在耐药组为25%、非耐药组为0%(P=0.03)。
- 35/36(97%)女性为FIGO低危组(风险评分0-6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To describe the sonographic characteristics of post-molar gestational trophoblastic neoplasia (GTN) at diagnosis and during follow-up, and to assess their association with methotrexate (MTX) resistance (R) as first-line chemotherapy.
METHODS: This was a retrospective study of all women treated for post-molar GTN at Karolinska University Hospital, Stockholm, Sweden, between October 2010 and December 2017, who had undergone expert transvaginal ultrasound assessment ≤ 2 weeks prior to, or ≤ 1 week after, the start of first-line MTX treatment. Women with a detectable uterine lesion were followed up with repeat scans during treatment, as well as after treatment in cases of persistent lesions. The association between MTX-R and sonographic findings at inclusion was assessed.
RESULTS: Of 47 eligible women, 36 were included in the analysis after excluding those who had not undergone structured transvaginal ultrasound assessment and those who started treatment at another center. The median age at diagnosis was 33 (interquartile range (IQR), 27-43) years and 35/36 (97%) women were in the FIGO low-risk group (risk score, 0-6). At inclusion, no uterine lesions were found in eight (22%) women, focal lesions in 24 (67%) women and global lesions in four (11%) women. Median maximum lesion diameter was 40.4 (IQR, 31.3-49.4) mm and 26/28 (93%) lesions had a color score of 3 or 4. Arteriovenous fistulas were found in 9/28 (32%) women and theca lutein cysts in 4/36 (11%) women. Four women with GTN lesion at inclusion underwent hysterectomy prior to the first follow-up ultrasound scan and a fifth woman with a growing lesion underwent hysterectomy, which revealed persistent viable trophoblastic tissue. All remaining women reached complete remission and median time to human chorionic gonadotropin normalization was 2.7 (IQR, 1.4-3.7) months. During ultrasound follow-up, 88% (21/24) of lesions resolved completely. Two women with a persisting lesion remained in complete remission. Median time to disappearance of vascularity was 5.8 (IQR, 3.7-9.3) months and median time to resolution of the lesion was 6.8 (IQR, 3.7-9.3) months. MTX-R developed in 12/31 (39%) women. Uterine tumors ≥ 4 cm (73% vs 17%; P = 0.008) and global lesions (25% vs 0%; P = 0.03) were significantly more common in women with compared to those without MTX-R.
CONCLUSION: Uterine lesions were detected at the time of diagnosis in 78% of women with post-molar GTN. The vast majority of the lesions resolved completely during follow-up, after a median of 7 months. MTX-R was more common in uterine tumors of 4 cm, or larger, and in global lesions. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Epstein E, Joneborg U. Sonographic characteristics of post-molar gestational trophoblastic neoplasia at diagnosis and during follow-up, and relationship with methotrexate resistance. Ultrasound Obstet Gynecol. 2020. PMID: 31909527. doi:10.1002/uog.21971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。